Drawing for CELLTRION

USPTO serial 79101488

CELLTRION

Reviewed by CopyMark Law Group

Reg. 4169803Status 739Registered
Filing date
Status date
Registration date
Jul 10, 2012
Examiner
COLEMAN, NICHOLAS A
Law office
GENERIC WEB UPDATE

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with CELLTRION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kisuk Lee

Kisuk Lee Harness, Dickey & Pierce, PLC7700 Bonhomme Avenue, Suite 400St. Louis, MO 63105UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005[ Vaccines; medicines for sensory organs, namely, pharmaceutical preparations for the treatment and prevention of disorders of sensory organ; agents affecting peripheral nervous system, namely, pharmaceutical preparations for the treatment and prevention of disorders of the peripheral nervous system; agents for immunity adjustment, namely, pharmaceutical preparations for the prevention and treatment of disorders of the immune system; biological preparations for medical purposes; amino acids for medical purposes; antibiotic preparations; agents for respiratory organs, namely, pharmaceutical preparations for the prevention and treatment of disorders of respiratory organs; chemotherapeutics; reagents for measuring Hepatitis B Surface antibody, namely, medical diagnostic reagents for detecting Hepatitis B surface antibody; diagnostic preparations for medical use; AIDS, acquired immune deficiency syndrome diagnostic agents, namely, diagnostic preparation for medical use; AIDS, acquired immune deficiency syndrome vaccines; agents affecting central nervous system, namely, pharmaceutical preparations for the treatment and prevention of disorders of the nervous system; veterinary vaccines; agents for tumor treatment, namely, pharmaceutical preparations for the treatment of tumor; agents for urogenital organs, namely, pharmaceutical preparations for the treatment and prevention of disorders of urogenital organs; kits for protein test, namely, diagnostic kits, namely, primary reagents for detecting the presence of a protein related to a disease; kits for gene test, namely, diagnostic kits, namely, primary reagents for detecting the presence of a gene related to a disease; biopharmaceuticals for the treatment and prevention of infectious diseases, tumor-related diseases, auto-immune diseases, hormone-deficiency diseases; biopharmaceutical preparations, namely, polypeptides, proteins, monoclonal antibodies, hormones for the treatment and prevention of infectious diseases, tumor-related diseases, auto-immune diseases, hormone deficiency diseases; biotherapeutic preparations and substances for medical purposes; biotechnological preparations for medical purposes; pharmaceuticals; chemical preparations for pharmaceutical purposes, namely, chemical reagents for medical purposes; chemico-pharmaceutical preparations ]SECTION 71 - CANCELLED—
035Wholesale distributorships featuring pharmaceutical products; retail store services featuring pharmaceutical products; business intermediary services in the field of pharmaceutical products; wholesale distributorships featuring biopharmaceutical products; retail store services featuring biopharmaceutical products; business intermediary services in the field of biopharmaceutical productsACTIVE—
040Treatment of biopharmaceutical materials, namely, processing finished products from raw biopharmaceutical materials; treatment service of biopharmaceutical materials for others, namely, processing finished products from raw biopharmaceutical materials for others; contract manufacturing service for others in the field of biopharmaceuticals; contract manufacturing service in the field of pharmaceuticalsACTIVE—
042Pharmaceutical research and development; [ bacteriological research; biological research; research and development for new products for others; material testing; chemistry services, namely, chemistry consultation; chemical research and analysis; technology outsourcing services on biopharmaceuticals manufacturing, namely, conducting biopharmaceutical research services for others; consulting services in the field of biotechnology; pharmaceutical drug development services with animal cell; scientific research related to genetically modified plant; biotechnology research; ] biopharmaceutical research and development [; medical product testing; technology outsourcing services on selecting medicines, namely, conducting pharmaceutical research services for others ]ACTIVE—
044[ Rental of medical and health care equipment; medical product information, namely, providing an interactive holistic web site featuring health information and patient initiated, patient authorized, fee-for-service, holistic approach distance healing sessions based on the patient's specific set of symptoms, medical profile and medical record analysis and patient benefit information concerning organic and holistic products and services; medical clinics, namely, conducting clinical trials of new products for medical purposes; hospitals; medical assistance services; biopharmaceutical consulting service ]SECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 21, 2023ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Dec 2, 2022ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Aug 17, 2022NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Aug 17, 2022C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Aug 16, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 18, 2022ES75TEAS SECTION 71 & 15 RECEIVED—
Oct 5, 2021CORNCORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Sep 18, 2021ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Sep 10, 2021CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Aug 6, 2021CHLDCHANGE OF OWNER RECEIVED FROM IB—
Jul 10, 2021REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Jul 2, 2021RNWLINTERNATIONAL REGISTRATION RENEWED—
Apr 30, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Apr 19, 2019INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Mar 23, 2019INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Mar 23, 2019INPCINVALIDATION PROCESSED—
Mar 20, 2019INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jul 20, 2018NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Jul 20, 201871.PREGISTERED - PARTIAL SEC 71 ACCEPTED—
Jul 18, 2018APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 21, 2018ES71TEAS SECTION 71 RECEIVED—
Jun 21, 2018EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Jul 10, 2017REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Mar 26, 2015ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Oct 11, 2013COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Oct 11, 2013PLGLASSIGNED TO PARALEGAL—
Oct 11, 2013LIMELIMITATION FROM THE IB EXAMINED AND ENTERED—
Aug 30, 2013LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Dec 2, 2012GPNXNOTIFICATION PROCESSED BY IB—
Nov 4, 2012FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 16, 2012FICSFINAL DISPOSITION NOTICE SENT TO IB—
Oct 16, 2012FIMPFINAL DISPOSITION PROCESSED—
Oct 10, 2012FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 10, 2012R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 24, 2012NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 24, 2012PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 4, 2012OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Apr 4, 2012OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Apr 4, 2012NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 19, 2012PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 19, 2012ALIEASSIGNED TO LIE—
Mar 2, 2012CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 2, 2012XAECEXAMINER'S AMENDMENT ENTERED—
Mar 2, 2012GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 2, 2012GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 2, 2012CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 15, 2011ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 15, 2011REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 18, 2011RFNTREFUSAL PROCESSED BY IB—
Sep 23, 2011RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 22, 2011RFRRREFUSAL PROCESSED BY MPU—
Sep 22, 2011RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 21, 2011CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 13, 2011MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 9, 2011DOCKASSIGNED TO EXAMINER—
Sep 9, 2011NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 8, 2011REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance